New-Onset Diabetes in the International Verapamil SR/Trandolapril Study (INVEST)

"Further analysis of the results of the International Verapamil SR/Trandolapril Study (INVEST) has confirmed that while calcium channel blocker (CCB)-based and beta-blocker-based strategies were equally effective in controlling blood pressure and preventing adverse outcomes in hypertensive subjects with coronary artery disease (CAD), the risk of new-onset diabetes in these patients was lower with the CCB-based strategy.[1] Addition of the angiotensin converting-enzyme (ACE) inhibitor trandolapril to verapamil SR lowered the risk of the primary outcome (all-cause death, nonfatal myocardial infarction [MI], or nonfatal stroke) and the risk of diabetes development, whereas addition of the diuretic hydrochlorothiazide (HCTZ) to atenolol, while lowering the risk of the primary outcome, increased the risk of diabetes development."